The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Immune Checkpoint Inhibitors Market Outlook 2022

Global Immune Checkpoint Inhibitors Market Outlook 2022

Publishing Date : Nov, 2021

License Type :
 

Report Code : 1634373

No of Pages : 106

Synopsis
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.

The global Immune Checkpoint Inhibitors market was valued at US$ 12550 million in 2020 and is expected to reach US$ 36030 million by the end of 2027, growing at a CAGR of 16.1% during 2021-2027.

This report focuses on Immune Checkpoint Inhibitors volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Immune Checkpoint Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Immune Checkpoint Inhibitors Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • PD-1/PD-L1
  • CTLA-4

Segment by Application

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancer
  • Other

By Region

  • North America (United States, Canada, Mexico)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, Other Regions)
  • Europe (Germany, U.K., France, Italy, Russia, Rest of Europe)
  • South America (Brazil, Argentina, Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, U.A.E., South Africa, Other Regions)

By Company

  • Bristol Myer Squibb
  • AstraZeneca
  • Merck
  • Roche / Genentech
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences

Scope of the Immune Checkpoint Inhibitors Market Report

Report Metric

Details

Report Name

Immune Checkpoint Inhibitors Market

Market size in 2020

US$ 12550 Million

The revenue forecast in 2027

US$ 36030 Million

Growth Rate

CAGR of 16.1% from 2021 to 2027

Market size available for years

2020-2027

Forecast units

Value (USD) & Volume (Units)

Segments covered

Types, End-User / Applications, Companies, and Region

Report coverage

Revenue & volume forecast, company share, competitive landscape, growth factors, and trends

Geographic regions covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

Index

1 Immune Checkpoint Inhibitors Market Overview
1.1 Product Overview and Scope of Immune Checkpoint Inhibitors
1.2 Immune Checkpoint Inhibitors Segment by Type
1.2.1 Global Immune Checkpoint Inhibitors Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 PD-1/PD-L1
1.2.3 CTLA-4
1.3 Immune Checkpoint Inhibitors Segment by Application
1.3.1 Global Immune Checkpoint Inhibitors Sales Comparison by Application: (2021-2027)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancer
1.3.8 Other
1.4 Global Immune Checkpoint Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Immune Checkpoint Inhibitors Revenue 2016-2027
1.4.2 Global Immune Checkpoint Inhibitors Sales 2016-2027
1.4.3 Immune Checkpoint Inhibitors Market Size by Region: 2016 Versus 2021 Versus 2027

2 Immune Checkpoint Inhibitors Market Competition by Manufacturers
2.1 Global Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2016-2021)
2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Immune Checkpoint Inhibitors Manufacturing Sites, Area Served, Product Type
2.5 Immune Checkpoint Inhibitors Market Competitive Situation and Trends
2.5.1 Immune Checkpoint Inhibitors Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Immune Checkpoint Inhibitors Players Market Share by Revenue
2.5.3 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Immune Checkpoint Inhibitors Retrospective Market Scenario by Region
3.1 Global Immune Checkpoint Inhibitors Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Immune Checkpoint Inhibitors Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.3.1 North America Immune Checkpoint Inhibitors Sales by Country
3.3.2 North America Immune Checkpoint Inhibitors Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.4.1 Europe Immune Checkpoint Inhibitors Sales by Country
3.4.2 Europe Immune Checkpoint Inhibitors Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Immune Checkpoint Inhibitors Market Facts & Figures by Region
3.5.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Region
3.5.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.6.1 Latin America Immune Checkpoint Inhibitors Sales by Country
3.6.2 Latin America Immune Checkpoint Inhibitors Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.7.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Country
3.7.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Immune Checkpoint Inhibitors Historic Market Analysis by Type
4.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
4.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2016-2021)
4.3 Global Immune Checkpoint Inhibitors Price by Type (2016-2021)

5 Global Immune Checkpoint Inhibitors Historic Market Analysis by Application
5.1 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
5.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2016-2021)
5.3 Global Immune Checkpoint Inhibitors Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Bristol Myer Squibb
6.1.1 Bristol Myer Squibb Corporation Information
6.1.2 Bristol Myer Squibb Description and Business Overview
6.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Portfolio
6.1.5 Bristol Myer Squibb Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.2.4 AstraZeneca Immune Checkpoint Inhibitors Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Merck Immune Checkpoint Inhibitors Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Roche / Genentech
6.4.1 Roche / Genentech Corporation Information
6.4.2 Roche / Genentech Description and Business Overview
6.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Roche / Genentech Immune Checkpoint Inhibitors Product Portfolio
6.4.5 Roche / Genentech Recent Developments/Updates
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Corporation Information
6.5.2 Ono Pharmaceutical Description and Business Overview
6.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Corporation Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Regeneron Immune Checkpoint Inhibitors Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Innovent
6.6.1 Innovent Corporation Information
6.6.2 Innovent Description and Business Overview
6.6.3 Innovent Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Innovent Immune Checkpoint Inhibitors Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Corporation Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Hengrui Medicine Immune Checkpoint Inhibitors Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Corporation Information
6.9.2 Junshi Biosciences Description and Business Overview
6.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Junshi Biosciences Immune Checkpoint Inhibitors Product Portfolio
6.9.5 Junshi Biosciences Recent Developments/Updates

7 Immune Checkpoint Inhibitors Manufacturing Cost Analysis
7.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
7.4 Immune Checkpoint Inhibitors Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Immune Checkpoint Inhibitors Distributors List
8.3 Immune Checkpoint Inhibitors Customers

9 Immune Checkpoint Inhibitors Market Dynamics
9.1 Immune Checkpoint Inhibitors Industry Trends
9.2 Immune Checkpoint Inhibitors Growth Drivers
9.3 Immune Checkpoint Inhibitors Market Challenges
9.4 Immune Checkpoint Inhibitors Market Restraints

10 Global Market Forecast
10.1 Immune Checkpoint Inhibitors Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Immune Checkpoint Inhibitors by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Immune Checkpoint Inhibitors by Type (2022-2027)
10.2 Immune Checkpoint Inhibitors Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Immune Checkpoint Inhibitors by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Immune Checkpoint Inhibitors by Application (2022-2027)
10.3 Immune Checkpoint Inhibitors Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Immune Checkpoint Inhibitors by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Immune Checkpoint Inhibitors by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Immune Checkpoint Inhibitors Sales (MT) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Immune Checkpoint Inhibitors Sales (MT) Comparison by Application (2021-2027)
Table 3. Global Immune Checkpoint Inhibitors Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Immune Checkpoint Inhibitors Covered in This Study
Table 5. Global Immune Checkpoint Inhibitors Sales (MT) of Key Manufacturers (2016-2021)
Table 6. Global Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Immune Checkpoint Inhibitors Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Immune Checkpoint Inhibitors Average Price (USD/Kg) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Immune Checkpoint Inhibitors Manufacturing Sites and Area Served
Table 11. Manufacturers Immune Checkpoint Inhibitors Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Immune Checkpoint Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Checkpoint Inhibitors as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Immune Checkpoint Inhibitors Sales by Region (2016-2021) & (MT)
Table 16. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
Table 17. Global Immune Checkpoint Inhibitors Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Immune Checkpoint Inhibitors Sales by Country (2016-2021) & (MT)
Table 19. North America Immune Checkpoint Inhibitors Sales Market Share by Country (2016-2021)
Table 20. North America Immune Checkpoint Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Immune Checkpoint Inhibitors Revenue Market Share by Country (2016-2021)
Table 22. Europe Immune Checkpoint Inhibitors Sales by Country (2016-2021) & (MT)
Table 23. Europe Immune Checkpoint Inhibitors Sales Market Share by Country (2016-2021)
Table 24. Europe Immune Checkpoint Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2016-2021) & (MT)
Table 27. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Immune Checkpoint Inhibitors Revenue Market Share by Region (2016-2021)
Table 30. Latin America Immune Checkpoint Inhibitors Sales by Country (2016-2021) & (MT)
Table 31. Latin America Immune Checkpoint Inhibitors Sales Market Share by Country (2016-2021)
Table 32. Latin America Immune Checkpoint Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Immune Checkpoint Inhibitors Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2016-2021) & (MT)
Table 35. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Immune Checkpoint Inhibitors Revenue Market Share by Country (2016-2021)
Table 38. Global Immune Checkpoint Inhibitors Sales (MT) by Type (2016-2021)
Table 39. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
Table 40. Global Immune Checkpoint Inhibitors Revenue (Million US$) by Type (2016-2021)
Table 41. Global Immune Checkpoint Inhibitors Revenue Share by Type (2016-2021)
Table 42. Global Immune Checkpoint Inhibitors Price (USD/Kg) by Type (2016-2021)
Table 43. Global Immune Checkpoint Inhibitors Sales (MT) by Application (2016-2021)
Table 44. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
Table 45. Global Immune Checkpoint Inhibitors Revenue (Million US$) by Application (2016-2021)
Table 46. Global Immune Checkpoint Inhibitors Revenue Share by Application (2016-2021)
Table 47. Global Immune Checkpoint Inhibitors Price (USD/Kg) by Application (2016-2021)
Table 48. Bristol Myer Squibb Corporation Information
Table 49. Bristol Myer Squibb Description and Business Overview
Table 50. Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 51. Bristol Myer Squibb Immune Checkpoint Inhibitors Product
Table 52. Bristol Myer Squibb Recent Developments/Updates
Table 53. AstraZeneca Corporation Information
Table 54. AstraZeneca Description and Business Overview
Table 55. AstraZeneca Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 56. AstraZeneca Immune Checkpoint Inhibitors Product
Table 57. AstraZeneca Recent Developments/Updates
Table 58. Merck Corporation Information
Table 59. Merck Description and Business Overview
Table 60. Merck Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 61. Merck Immune Checkpoint Inhibitors Product
Table 62. Merck Recent Developments/Updates
Table 63. Roche / Genentech Corporation Information
Table 64. Roche / Genentech Description and Business Overview
Table 65. Roche / Genentech Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 66. Roche / Genentech Immune Checkpoint Inhibitors Product
Table 67. Roche / Genentech Recent Developments/Updates
Table 68. Ono Pharmaceutical Corporation Information
Table 69. Ono Pharmaceutical Description and Business Overview
Table 70. Ono Pharmaceutical Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 71. Ono Pharmaceutical Immune Checkpoint Inhibitors Product
Table 72. Ono Pharmaceutical Recent Developments/Updates
Table 73. Regeneron Corporation Information
Table 74. Regeneron Description and Business Overview
Table 75. Regeneron Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 76. Regeneron Immune Checkpoint Inhibitors Product
Table 77. Regeneron Recent Developments/Updates
Table 78. Innovent Corporation Information
Table 79. Innovent Description and Business Overview
Table 80. Innovent Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 81. Innovent Immune Checkpoint Inhibitors Product
Table 82. Innovent Recent Developments/Updates
Table 83. Hengrui Medicine Corporation Information
Table 84. Hengrui Medicine Description and Business Overview
Table 85. Hengrui Medicine Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 86. Hengrui Medicine Immune Checkpoint Inhibitors Product
Table 87. Hengrui Medicine Recent Developments/Updates
Table 88. Junshi Biosciences Corporation Information
Table 89. Junshi Biosciences Description and Business Overview
Table 90. Junshi Biosciences Immune Checkpoint Inhibitors Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 91. Junshi Biosciences Immune Checkpoint Inhibitors Product
Table 92. Junshi Biosciences Recent Developments/Updates
Table 93. Production Base and Market Concentration Rate of Raw Material
Table 94. Key Suppliers of Raw Materials
Table 95. Immune Checkpoint Inhibitors Distributors List
Table 96. Immune Checkpoint Inhibitors Customers List
Table 97. Immune Checkpoint Inhibitors Market Trends
Table 98. Immune Checkpoint Inhibitors Growth Drivers
Table 99. Immune Checkpoint Inhibitors Market Challenges
Table 100. Immune Checkpoint Inhibitors Market Restraints
Table 101. Global Immune Checkpoint Inhibitors Sales Forecast by Type (2022-2027) & (MT)
Table 102. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Type (2022-2027)
Table 103. Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 104. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Type (2022-2027)
Table 105. Global Immune Checkpoint Inhibitors Sales Forecast by Application (2022-2027) & (MT)
Table 106. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Application (2022-2027)
Table 107. Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 108. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Application (2022-2027)
Table 109. Global Immune Checkpoint Inhibitors Sales Forecast by Region (2022-2027) & (MT)
Table 110. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Region (2022-2027)
Table 111. Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 112. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Region (2022-2027)
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Immune Checkpoint Inhibitors
Figure 2. Global Immune Checkpoint Inhibitors Market Share by Type in 2020 & 2027
Figure 3. PD-1/PD-L1 Product Picture
Figure 4. CTLA-4 Product Picture
Figure 5. Global Immune Checkpoint Inhibitors Market Share by Application in 2020 & 2027
Figure 6. Lung Cancer
Figure 7. Colorectal Cancer
Figure 8. Breast Cancer
Figure 9. Prostate Cancer
Figure 10. Melanoma
Figure 11. Blood Cancer
Figure 12. Other
Figure 13. Global Immune Checkpoint Inhibitors Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Immune Checkpoint Inhibitors Market Size 2016-2027 (US$ Million)
Figure 15. Global Immune Checkpoint Inhibitors Sales 2016-2027 (MT)
Figure 16. Global Immune Checkpoint Inhibitors Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 17. Immune Checkpoint Inhibitors Sales Share by Manufacturers in 2020
Figure 18. Global Immune Checkpoint Inhibitors Revenue Share by Manufacturers in 2020
Figure 19. The Global 5 and 10 Largest Immune Checkpoint Inhibitors Players: Market Share by Revenue in 2020
Figure 20. Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 21. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
Figure 22. Global Immune Checkpoint Inhibitors Sales Market Share by Region in 2020
Figure 23. Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2016-2021)
Figure 24. Global Immune Checkpoint Inhibitors Revenue Market Share by Region in 2020
Figure 25. U.S. Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Canada Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Germany Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. France Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. U.K. Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Italy Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Russia Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. China Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Japan Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. South Korea Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. India Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Australia Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Taiwan Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Indonesia Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Thailand Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Malaysia Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Philippines Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Vietnam Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Mexico Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Brazil Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Argentina Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Turkey Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Saudi Arabia Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. U.A.E Immune Checkpoint Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Sales Market Share of Immune Checkpoint Inhibitors by Type (2016-2021)
Figure 50. Sales Market Share of Immune Checkpoint Inhibitors by Application (2016-2021)
Figure 51. Sales Market Share of Immune Checkpoint Inhibitors by Application in 2020
Figure 52. Revenue Share of Immune Checkpoint Inhibitors by Application (2016-2021)
Figure 53. Revenue Share of Immune Checkpoint Inhibitors by Application in 2020
Figure 54. Manufacturing Cost Structure of Immune Checkpoint Inhibitors
Figure 55. Manufacturing Process Analysis of Immune Checkpoint Inhibitors
Figure 56. Immune Checkpoint Inhibitors Industrial Chain Analysis
Figure 57. Channels of Distribution
Figure 58. Distributors Profiles
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’